Why Lactulose is Given in Decompensated Chronic Liver Disease
Lactulose is given to patients with decompensated chronic liver disease (DCLD) primarily to treat and prevent hepatic encephalopathy (HE), a neuropsychiatric complication that occurs when the failing liver cannot adequately clear ammonia and other toxins from the blood. 1
Primary Mechanism of Action
Lactulose works through multiple complementary mechanisms in the gut 1:
- Reduces intestinal pH by bacterial degradation into acetic and lactic acids, creating an acidic environment
- Converts ammonia to ammonium, which is less absorbable and trapped in the intestinal lumen
- Increases lactobacillus counts, bacteria that do not produce ammonia
- Creates osmotic laxative effect that flushes ammonia and toxins out of the gut
- Increases bacterial nitrogen incorporation, reducing ammonia production from other nitrogen-containing compounds
The FDA label confirms lactulose reduces blood ammonia levels by 25-50%, with clinical response observed in approximately 75% of patients 2.
Clinical Indications in DCLD
Treatment of Overt Hepatic Encephalopathy
When overt HE occurs, administer 30-45 mL of lactulose (20-30 g) every 1-2 hours orally until the patient has at least 2 bowel movements per day 1. Thereafter, titrate to achieve 2-3 soft stools daily 1.
For severe HE (West-Haven grade 3 or higher) when oral administration is not possible, perform lactulose enema with 300 mL lactulose and 700 mL water 3-4 times daily, retaining the solution for at least 30 minutes 1.
Secondary Prophylaxis
Lactulose is recommended as secondary prophylaxis following a first episode of overt HE 3. An RCT demonstrated that patients receiving lactulose after HE recovery had a 14-month recurrence risk of 20% versus 47% in those not receiving lactulose 3. Another study showed lactulose reduced HE recurrence from 46.8% to 19.6% over 14 months of follow-up 4.
Meta-analyses confirm lactulose is more effective than placebo in preventing overt HE episodes (RR 0.62,95% CI 0.46-0.84; and RR 0.63,95% CI 0.53-0.74) 1.
Clinical Efficacy and Outcomes
Lactulose therapy leads to recovery in 70-90% of HE patients 1. Beyond treating encephalopathy, lactulose:
- Improves quality of life 5
- Increases rate of recovery from overt HE 5
- Improves survival rates 5
- Increases protein tolerance 2
Practical Dosing Algorithm
Initial acute treatment:
- Start 30-45 mL (20-30 g) every 1-2 hours until 2 bowel movements occur
- Then switch to maintenance dosing
Maintenance dosing:
- 20-30 g orally 3-4 times daily 1
- Titrate to achieve 2-3 soft stools per day
- If oral route unavailable, use nasogastric tube 1
Severe cases (Grade 3-4 HE):
Important Caveats
Avoid excessive bowel movements that can lead to dehydration and electrolyte disturbances, particularly hypokalemia, which can paradoxically worsen HE 2, 5. The FDA label specifically warns that infants may develop hyponatremia and dehydration 2.
Use with caution in diabetics as lactulose contains galactose (<1.6 g/15 mL) and lactose (<1.2 g/15 mL) 2.
Avoid concurrent use of other laxatives during initial therapy, as loose stools may falsely suggest adequate lactulose dosing has been achieved 2.
Monitor for drug interactions: Non-absorbable antacids may inhibit the desired pH drop in the colon, and neomycin may interfere with bacterial degradation of lactulose, though evidence is conflicting 2.
When to Add Rifaximin
Add rifaximin 550 mg twice daily to lactulose when patients experience >1 additional HE episode within 6 months of the first one 3, 6. Combination therapy shows better recovery rates (76% vs 44%, P=0.004) and shorter hospital stays (5.8 vs 8.2 days, P=0.001) compared to lactulose alone 1.
The combination approach is supported by high-quality evidence showing rifaximin plus lactulose reduces HE recurrence risk from 45.9% to 22.1% (number needed to treat = 4) 3.